Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
41.44
-0.17 (-0.41%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gsk Plc ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
28
29
Next >
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
January 18, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."
Via
Benzinga
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
January 18, 2023
Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday.
Via
Benzinga
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
January 17, 2023
Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines.
Via
Investor's Business Daily
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
January 07, 2023
WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to...
Via
Talk Markets
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
January 06, 2023
CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.
Via
InvestorPlace
GSK's Debt Overview
December 06, 2022
Over the past three months, shares of GSK Inc. (NYSE:GSK) moved higher by 19.05%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...
Via
Benzinga
GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
November 14, 2022
Via
Benzinga
GSK Limits Second-Line Maintenance Use Of Its Ovarian Cancer Drug To Some Populations
November 11, 2022
Via
Benzinga
The Year of the Tripledemic
January 03, 2023
The Year of the Tripledemic
Via
News Direct
Topics
Death
Exposures
COVID-19
Death
What You Missed On Wall Street On Friday
December 31, 2022
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.
Via
Talk Markets
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'
Via
Benzinga
7 Drug Stocks That Will Soar in 2023
December 22, 2022
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.
Via
InvestorPlace
2 Smartest Tech Stocks to Buy in 2022 and Beyond
December 20, 2022
The tech space is still bursting with opportunities for long-term investors.
Via
The Motley Fool
Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says
December 14, 2022
Via
Benzinga
Options Trader Betting On GSK Stock Rising Heading Into 2023
December 13, 2022
Options traders are making big bets on the upside for healthcare, particularly in shares of GSK plc (NYSE: GSK).
Via
Benzinga
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
December 13, 2022
Via
Benzinga
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
December 08, 2022
Via
Benzinga
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
December 07, 2022
Via
Benzinga
Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07
December 07, 2022
Benzinga
Via
Benzinga
Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac
December 07, 2022
Via
Benzinga
These 3 Stocks Escaped Tuesday's Market Downdraft
December 06, 2022
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Via
The Motley Fool
Why GSK Plc And Sanofi SA Stock Are Shooting Higher
December 06, 2022
Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.
Via
Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
November 25, 2022
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...
Via
Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
November 25, 2022
Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.
Via
Benzinga
After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US
November 22, 2022
Via
Benzinga
Dividend Income Update October 2022
November 17, 2022
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio.
Via
Talk Markets
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
Via
Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
November 15, 2022
Via
Benzinga
Peering Into GSK's Recent Short Interest
November 15, 2022
GSK's (NYSE:GSK) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.7% of all regular shares that are...
Via
Benzinga
Daily Stock Analysis: GSK plc
November 15, 2022
By my dogcatcher ideal, this is a likely time to buy GSK plc shares based on their dividends for the coming year 2022-23.
Via
Talk Markets
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.